Biweekly Chemo Duo Shows Promise for Pancreatic Cancer Patients Over 75

Pancreatic cancer remains one of medicine’s most unforgiving adversaries, claiming lives at a rate that has made it the third leading cause of cancer-related death in both the United States and Japan. Yet the patients most likely to face it are precisely those most likely to be excluded from the trials that define modern treatment: adults aged 75 and older, who make up roughly 37 percent of new diagnoses in the United States but who remain strikingly underrepresented in the pivotal studies that established today’s standard of care. Now, a prospective Phase II trial conducted at the Osaka International Cancer Institute in Japan offers what researchers describe as promising, age-specific evidence that a modified chemotherapy schedule can deliver meaningful tumor control in this population while keeping toxicity at a clinically manageable level.

The trial, published in Cancer Reports, evaluated a biweekly regimen of gemcitabine plus nab-paclitaxel, a two-drug combination widely known by the abbreviation GnP. In its conventional form, GnP is administered on Days 1, 8, and 15 of a 28-day cycle, a schedule validated by the landmark MPACT trial, which demonstrated a survival advantage over gemcitabine alone in patients with metastatic disease. The Osaka team instead delivered both agents on Days 1 and 15 only, at the standard doses of gemcitabine 1000 mg/m2 and nab-paclitaxel 125 mg/m2, reasoning that fewer infusions per cycle might ease the burden on older bodies without sacrificing efficacy. Retrospective studies of biweekly GnP in broader populations had already hinted at feasibility, reporting median overall survival of around 10 months, but prospective data in patients aged 75 and older had been essentially absent.

Seventeen patients with unresectable pancreatic cancer, either locally advanced or metastatic, enrolled between August 2019 and March 2021. Their median age was 77, with a range of 75 to 81 years, and the vast majority, 76.5 percent, had metastatic disease. All were required to have an Eastern Cooperative Oncology Group performance status of 0 or 1, indicating they were still fully ambulatory or capable of light activity, along with adequate blood counts, liver function, and kidney function. The researchers also used the Geriatric-8 screening tool, an eight-item questionnaire designed to capture vulnerabilities that standard performance measures miss, and scores ranged widely from 6 to 17, a reminder that chronological age conceals substantial heterogeneity in physical reserve. Notably, 12 of the 17 patients had hypertension, 7 had hyperlipidemia, and 6 had diabetes, reflecting the comorbidity burden typical of this age group.

The trial employed Simon’s two-stage minimax design, a statistical framework that allows early stopping if a regimen appears unacceptably ineffective. With an expected overall response rate of 30 percent and a rejection threshold of 7 percent, the study required 18 evaluable patients. Seven patients were assessed in the first stage, and once at least one tumor response was confirmed, the trial advanced to its second stage. Planned enrollment was 20 patients, but accrual ended at 17 due to an unstable supply of nab-paclitaxel during the study period, a practical setback that the authors acknowledge constrained the final statistical power of the efficacy analysis.

Despite the smaller-than-planned cohort, the efficacy signals were striking. At the March 31, 2023 data cutoff, with a median follow-up of 16.8 months, the confirmed overall response rate reached 47.1 percent, with all eight responders achieving partial responses. The 95 percent confidence interval ranged from 23.0 to 72.2 percent, comfortably exceeding the prespecified expectation of 30 percent. The disease control rate, which combines complete and partial responses with stable disease, stood at 82.4 percent. Median overall survival was 16.8 months and median progression-free survival was 8.3 months, figures that sit squarely within the range reported for standard three-times-per-cycle GnP in pivotal trials, including the GENERATE (JCOG1611) trial in Japanese patients, which reported median overall survival of 17.1 months in a cohort capped at age 75. One- and two-year survival rates were 58.8 and 29.4 percent, respectively.

Safety results, however, temper any temptation toward celebration. Every patient experienced at least one adverse event, and grade 3 or higher events of any cause occurred in 52.9 percent of the cohort, with treatment-related severe events in 29.4 percent. The most common toxicities of any grade included anemia in 88.2 percent, alopecia in 88.2 percent, decreased white blood cell count in 76.5 percent, fatigue in 76.5 percent, and peripheral sensory neuropathy in 64.7 percent. Among treatment-related severe events, neutropenia led at 17.6 percent. Seven patients experienced serious adverse events, two of which were judged related to the study drugs. No treatment-related deaths occurred, and no patient died from any adverse event during the study, an outcome the investigators emphasize as meaningful in such a fragile population.

Treatment delivery also revealed the limits of any fixed schedule in older adults. Although the biweekly design meant fewer planned infusions, 11 of 17 patients, 64.7 percent, still required at least one dose reduction, most often of nab-paclitaxel, whose median relative dose intensity fell to 87.3 percent compared with 100 percent for gemcitabine. Three patients discontinued protocol treatment because of adverse events: two for peripheral sensory neuropathy and one for grade 2 interstitial pneumonia, all of whom recovered and moved on to subsequent therapy. The authors argue that the frequency of dose reduction underscores that individualized dose adjustment remains essential even under a deliberately gentler schedule, and they suggest that clinicians may reasonably consider starting at a reduced dose in patients with greater geriatric vulnerability, though the study cannot define precise criteria for that decision.

An intriguing exploratory finding was that survival was actually shorter in the four patients with locally advanced disease than in the thirteen with metastatic disease, a reversal of the usual prognostic pattern. The investigators attribute this largely to the very small subgroup size, which makes estimates unstable, and to baseline characteristics suggesting that the locally advanced patients tended to have poorer performance status and lower Geriatric-8 scores. Exploratory analyses confirmed that patients with performance status 0 fared better than those with status 1, while the Geriatric-8 stratification was too small to interpret. What was unambiguous, however, was the role of subsequent treatment: 14 of the 17 patients, 82.4 percent, went on to receive further systemic therapy after stopping the study regimen, most commonly the oral fluoropyrimidine S-1 or fluorouracil plus nanoliposomal irinotecan, and previous research has consistently shown that effective second-line therapy extends survival in advanced pancreatic cancer.

Beyond the numbers, the study raises a question that oncologists increasingly regard as central to geriatric care: the concept of time toxicity, the share of a patient’s remaining life consumed by treatment itself. Real-world data suggest that pancreatic cancer patients receiving palliative chemotherapy spend roughly 10 percent of their remaining life on healthcare-related activities. A biweekly schedule involves fewer clinic visits per cycle than the conventional regimen, and while this trial did not measure time toxicity prospectively, the authors argue the potential convenience benefit deserves rigorous comparative evaluation. They are equally candid about the study’s limitations: it was single-center, single-arm, and small, enrolled only Japanese patients, excluded frail patients through strict performance and organ-function criteria, and did not perform comprehensive geriatric assessment. Still, in a disease where evidence for patients over 75 has long been extrapolated from younger cohorts, the trial delivers something genuinely scarce: prospective, age-specific data showing that a thoughtfully modified regimen can achieve response rates and survival figures comparable to those of standard protocols, and that, with careful monitoring, many older adults can tolerate and benefit from active combination chemotherapy rather than being consigned to monotherapy or supportive care alone.

Subject of Research: Biweekly gemcitabine plus nab-paclitaxel as first-line therapy for pancreatic cancer patients aged 75 and older

Article Title: Prospective Phase II Trial of Biweekly Gemcitabine Plus Nab‐Paclitaxel as First‐Line Therapy in Patients Aged 75 Years and Older With Unresectable Pancreatic Cancer

Article References: Ikezawa, K., Imai, T., Takada, R., Yamai, T., Fukutake, N., Urabe, M., Kai, Y., Mukai, K., Nakabori, T., & Ohkawa, K. (2026). Prospective Phase II Trial of Biweekly Gemcitabine Plus Nab‐Paclitaxel as First‐Line Therapy in Patients Aged 75 Years and Older With Unresectable Pancreatic Cancer. Cancer Reports, 9(9), Article e70691. https://doi.org/10.1002/cnr2.70691

Image Credits: AI Generated

DOI: 10.1002/cnr2.70691

Keywords: pancreatic cancer, gemcitabine, nab-paclitaxel, biweekly chemotherapy, elderly patients, Phase II trial, unresectable disease, overall response rate, peripheral neuropathy, geriatric assessment, overall survival, oncology